Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Blarcamesine

Small molecule · developed by Anavex Life Sciences

Phase 2/3 Most advanced trial (none active)
AVXL Developer
2 Registered trials

What is Blarcamesine?

Blarcamesine (ANAVEX2-73) is an oral drug studied in Rett syndrome and Alzheimer disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ANAVEX2-73
Drug type
Small molecule
Therapy area
Neurology
Developer
Anavex Life Sciences Corp. (AVXL)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
9T210MMZ3F

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04304482 Phase 2/3 Rett Syndrome Completed AVXL
NCT04314934 Phase 2/3 Alzheimer Disease Completed AVXL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Alzheimer DiseaseRett Syndrome

More from Anavex Life Sciences

Follow AVXL, the company behind Blarcamesine

See AVXL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVXL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.